Hanson & Doremus Investment Management Raises Stake in Novo Nordisk A/S (NYSE:NVO)

Hanson & Doremus Investment Management grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 6,578.9% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,076 shares of the company's stock after purchasing an additional 5,000 shares during the quarter. Hanson & Doremus Investment Management's holdings in Novo Nordisk A/S were worth $437,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. International Assets Investment Management LLC increased its stake in Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company's stock worth $215,942,000 after acquiring an additional 1,796,635 shares during the last quarter. Mediolanum International Funds Ltd bought a new position in Novo Nordisk A/S during the third quarter valued at $98,765,000. Wellington Management Group LLP bought a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth about $42,017,000. Sanctuary Advisors LLC bought a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at about $41,646,000. Finally, World Investment Advisors LLC grew its position in Novo Nordisk A/S by 2,655.9% in the third quarter. World Investment Advisors LLC now owns 280,409 shares of the company's stock worth $33,388,000 after acquiring an additional 270,234 shares in the last quarter. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Up 2.0 %

Shares of Novo Nordisk A/S stock traded up $1.70 on Thursday, reaching $85.73. The stock had a trading volume of 3,654,163 shares, compared to its average volume of 9,523,373. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The company has a 50 day moving average price of $94.32 and a 200 day moving average price of $113.82. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $384.69 billion, a P/E ratio of 27.70, a P/E/G ratio of 0.90 and a beta of 0.45.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on NVO shares. Sanford C. Bernstein raised Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. BNP Paribas raised shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, December 2nd. Cantor Fitzgerald reissued an "overweight" rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. UBS Group raised Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. Finally, BMO Capital Markets cut their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research report on Monday, December 23rd. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of "Buy" and an average price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.